ReviewCold Spring Harbor perspectives in medicine2019
Adaptive Immune Responses in Hepatitis A Virus and Hepatitis E Virus Infections.
Review in Cold Spring Harbor perspectives in medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 73 citations in OpenAlex.
- Long-term protection from naturally acquired immunity against hepatitis E virus reinfection.Nature communications · 2025Trial
- T-cell receptor repertoires as potential diagnostic markers for patients with COVID-19.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Trial
- Immunological consequences of delayed exposure to hepatitis A virus: evidence consistent with CD8BMC infectious diseases · 2026Article
- Seroprevalence of Hepatitis A Virus (HAV) and Hepatitis E Virus (HEV) Among Blood Donor Candidates in Salvador, Bahia, Brazil.Viruses · 2026Article
- Targeting the innate immune system in treating hepatitis B: prospects for functional cure.Clinical and molecular hepatology · 2026Review
- Virological and immunological determinants of hepatitis E virus infection outcomes.Current opinion in virology · 2025Review
- Article
- Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses.Biological procedures online · 2025Review
- Structural basis for hepatitis E virus neutralization by potent human antibodies.Science advances · 2025Article
- Atomic force microscopy at the forefront: unveiling foodborne viruses with biophysical tools.Npj viruses · 2025Review
- Redefining the immune landscape of hepatitis A virus infection.Experimental & molecular medicine · 2025Review
- Broadly neutralizing antibodies isolated from HEV convalescents confer protective effects in human liver-chimeric mice.Nature communications · 2025Article
- Sequence Matters: Primary COVID-19 Vaccination after Infection Elicits Similar Anti-spike Antibody Levels, but Stronger Antibody Dependent Cell-mediated Cytotoxicity than Breakthrough Infection.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Hepatitis E virus: from innate sensing to adaptive immune responses.Nature reviews. Gastroenterology & hepatology · 2024Review
- Unveiling the Burden of Hepatitis A in Salerno, Italy: A Comprehensive 9-Year Retrospective Study (2015-2023) on the Seroprevalence of HAV Antibodies and Age/Sex Distribution.Journal of clinical medicine · 2024Article
- Viral Hepatitis: Host Immune Interaction, Pathogenesis and New Therapeutic Strategies.Pathogens (Basel, Switzerland) · 2024Review
- Pathogenesis and clinical features of severe hepatitis E virus infection.World journal of virology · 2024Review
- An experimental chimeric hepatitis E virus vaccine elicits both local and systemic immune responses.Frontiers in microbiology · 2024Article
- HAV-induced acalculous cholecystitis: A case report and literature review.Clinical case reports · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Both hepatitis A virus (HAV) and hepatitis E virus (HEV) cause self-limited infections in humans that are preventable by vaccination. Progress in characterizing adaptive immune responses against these enteric hepatitis viruses, and how they contribute to resolution of infection or liver injury, has therefore remained largely frozen for the past two decades. How HAV and HEV infections are so effectively controlled by B- and T-cell immunity, and why they do not have the same propensity to persist as HBV and HCV infections, cannot yet be adequately explained. The objective of this review is to summarize our understanding of the relationship between patterns of virus replication, adaptive immune responses, and acute liver injury in HAV and HEV infections. Gaps in knowledge, and recent studies that challenge long-held concepts of how antibodies and T cells contribute to control and pathogenesis of HAV and HEV infections, are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.